The FDA has approved an additional indication for Merck’s Ebola vaccine, Ervebo, allowing it to be administered to infants as young as 12 months old. Previously, the vaccination had only been licensed for people over the age of 18. The vaccine contains an Ebola virus gene that permits the body to develop protection against the virus without risk of infection. The data from the clinical trials showed that the vaccine elicited an efficient immune response in both adults and children, with antibody levels much exceeding what is considered protective against the Ebola virus. The vaccine’s increased approval will help protect more vulnerable young children from the deadly Ebola virus.

To know more: About the original article click here.